Bhargava A, Jackson W B, El-Defrawy S R
Department of Ophthalmology, University of Ottawa Eye Institute, Ottawa, Ontario, Canada.
Drugs Today (Barc). 1998 Nov;34(11):957-71. doi: 10.1358/dot.1998.34.11.487480.
Ocular allergy is a common condition that usually affects the conjunctiva of the eye and is therefore often referred to as allergic conjunctivitis. The severity of the disease can range from mild itching and redness, as seen in seasonal allergic conjunctivitis, to the more serious vision threatening forms of ocular allergy which affect the cornea, such as atopic keratoconjunctivitis. The pathogenesis of allergic conjunctivitis involves a complex mechanism which centers around IgE-mediated mast cell degranulation and release of multiple preformed and newly formed inflammatory mediators. The diagnosis of allergic conjunctivitis is usually a clinical one which can be made based on a thorough history and careful examination. Treatment of ocular allergy should begin with conservative measures including allergen avoidance, environmental control, ocular irrigation and cold compresses. Pharmacotherapy of allergic conjunctivitis consists of several classes of drugs. Antihistamines are widely used to treat mild conditions such as seasonal and perennial conjunctivitis and potent new agents such as levocabastine and emedastine are now available. Mast cell stabilizers such as sodium cromoglycate are both safe and effective and are commonly used in ocular allergy. More effective mast cell stabilizers such as nedocromil, lodoxamide and olopatadine are now being used. Nonsteroidal antiinflammatory drugs have demonstrated only limited efficacy and, as such, are not widely used. Topical steroids are very effective in treating signs and symptoms but are reserved for only refractory cases due to their serious side effects. Loteprednol and rimexelone are newer corticosteroids which reportedly have less of an effect on intraocular pressure. Cyclosporine has recently been shown to be highly effective in cases of vernal keratoconjunctivitis and atopic keratoconjunctivitis while producing no adverse effects.
眼部过敏是一种常见病症,通常影响眼睛的结膜,因此常被称为过敏性结膜炎。该疾病的严重程度不一,从季节性过敏性结膜炎中出现的轻度瘙痒和发红,到影响角膜的更严重的、威胁视力的眼部过敏形式,如特应性角结膜炎。过敏性结膜炎的发病机制涉及一个复杂的过程,其核心是免疫球蛋白E(IgE)介导的肥大细胞脱颗粒以及多种预先形成和新形成的炎症介质的释放。过敏性结膜炎的诊断通常基于临床,可通过详尽的病史和仔细的检查来做出。眼部过敏的治疗应从保守措施开始,包括避免接触过敏原、环境控制、眼部冲洗和冷敷。过敏性结膜炎的药物治疗包括几类药物。抗组胺药广泛用于治疗轻度病症,如季节性和常年性结膜炎,现在有左卡巴斯汀和依美斯汀等强效新药可供使用。肥大细胞稳定剂,如色甘酸钠,既安全又有效,常用于眼部过敏治疗。现在正在使用更有效的肥大细胞稳定剂,如奈多罗米、洛度沙胺和奥洛他定。非甾体抗炎药仅显示出有限的疗效,因此未被广泛使用。局部用类固醇在治疗体征和症状方面非常有效,但由于其严重的副作用,仅用于难治性病例。洛替泼诺和利美索龙是较新的皮质类固醇,据报道它们对眼压的影响较小。环孢素最近已被证明在春季角结膜炎和特应性角结膜炎病例中非常有效,且无不良反应。